RecruitingPhase 1NCT07241104

A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy

A Phase I First-in-human Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD4063 in Adults With Phospholamban R14del Dilated Cardiomyopathy

Sponsor

AstraZeneca

Enrollment

31 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Dilated Cardiomyopathy

Summary

The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AZD4063 for people with dilated cardiomyopathy. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.